NCT04905342 - NVP-1805 Compared to Coadministration of NVP-1805-R1 With NVP-1805-R2 in Healthy Adult Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 14, 2021

Primary Completion Date

December 20, 2021

Study Completion Date

January 7, 2022

Conditions

Healthy Volunteers

Interventions

DRUG

NVP-1805

orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4) (NVP-1805 80/10/20.8mg)

DRUG

NVP-1805-R1and NVP-1805-R2

orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4) (NVP-1805-R1 80mg, NVP-1805-R2 10/20.8mg)

Trial Locations (1)

H Plus Yangji Hospital, Seoul